门诊经尿道前列腺手术后再次手术与急性尿潴留的索赔数据评估
基于纽约州数据库纳入15,982例40岁以上因良性前列腺增生接受门诊经尿道手术的男性,比较不同术式7年治疗失败率。结果显示绿激光汽化术与经尿道电切术失败风险无差异,内镜下剜除术失败率可能更低但使用不足,其他术式失败风险显著更高。
要点
- 门诊经尿道前列腺手术7年累积失败率:电切15.3%,绿激光13.9%,剜除6.7%,其他17.8%。
- 与电切相比,绿激光汽化术治疗失败风险无显著增加(HR 1.07, 95%CI 0.93-1.22)。
- 内镜剜除术失败风险有降低趋势(HR 0.67, 95%CI 0.36-1.22),其他术式风险显著升高(HR 1.68, 95%CI 1.12-2.52)。
核心结论
- 门诊绿激光汽化术与经尿道电切术7年治疗失败率无差异。
- 内镜剜除术虽使用不足但可能与更低治疗失败率相关。
- 其他经尿道术式(尿道切开、微波/射频消融)失败风险显著更高。
研究设计与样本
- 基于纽约州SPARCS数据库的回顾性队列研究,纳入2010至2016年40岁以上接受门诊经尿道前列腺手术的男性15,982例。
- 中位年龄69岁(IQR 63-76),61%接受绿激光汽化术,36%经尿道电切术,1.5%内镜剜除术,1.5%其他术式。
- 采用多因素Cox比例风险回归预测治疗失败(术后30天以上再次手术或急性尿潴留)。
主要发现
- 7年累积失败率:经尿道电切术15.3%,绿激光汽化术13.9%,内镜剜除术6.7%,其他术式17.8%。
- 与电切术相比,绿激光汽化术治疗失败HR 1.07(95%CI 0.93-1.22)。
- 内镜剜除术HR 0.67(95%CI 0.36-1.22),其他术式HR 1.68(95%CI 1.12-2.52)。
- 2011至2012年接受内镜剜除术者失败风险显著低于电切术(HR 0.24, 95%CI 0.06-0.97)。
关键数值与推荐
- 治疗失败定义为术后30天以上再次手术或急性尿潴留。
- 与电切术相比,绿激光汽化术HR 1.07(95%CI 0.93-1.22)。
- 与电切术相比,内镜剜除术HR 0.67(95%CI 0.36-1.22)。
- 与电切术相比,其他术式HR 1.68(95%CI 1.12-2.52)。
- 2011至2012年亚组内镜剜除术对比电切术HR 0.24(95%CI 0.06-0.97)。
临床怎么用
- 门诊绿激光汽化术可作为经尿道电切术的替代选择,7年再手术或尿潴留风险相当。
- 内镜剜除术可能降低远期治疗失败率,但需注意本研究中使用率仅1.5%。
- 其他经尿道术式(尿道切开、微波/射频消融)治疗失败风险较高,选择时应谨慎。
局限性
- 回顾性索赔数据库研究,可能存在编码偏倚和混杂因素。
- 内镜剜除术和其他术式样本量小(各1.5%),结果置信区间宽。
- 缺乏症状评分、前列腺体积等临床细节,治疗失败定义依赖再手术和尿潴留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated real-world use of common transurethral prostate procedures in the ambulatory surgical setting and compare subsequent rates of tr!eatment failure. MATERIALS AND METHODS: Using the New York Statewide Planning and Research Cooperative System database we identified men 40 years old or older undergoing ambulatory surgeries categorized as transurethral resection of the prostate, photoselective vaporization of the prostate, endoscopic enucleation or other (transurethral incision, microwave/radiofrequency ablation) from 2010 to 2016. Multivariate Cox proportional hazards regression was used to predict treatment failure, defined as reoperation or postoperative acute urinary retention greater than 30 days after procedure. RESULTS: We identified 15,982 men, median age 69 years (IQR 63-76), 61% of whom underwent photoselective vaporization of the prostate, 36% transurethral resection of the prostate, 1.5% endoscopic enucleation and 1.5% other transurethral prostate procedures from 2010 to 2016. At 7 years cumulative failure rates were 15.3% (transurethral resection of the prostate), 13.9% (photoselective vaporization of the prostate), 6.7% (endoscopic enucleation) and 17.8% (other procedures). Compared to transurethral resection of the prostate, photoselective vaporization of the prostate was not associated with increased hazards of treatment failure HR 1.07 (95% CI 0.93-1.22). Compared to transurethral resection of the prostate, endoscopic enucleation was associated with a nonsignificant trend toward lower treatment failure (HR 0.67, 95% CI 0.36-1.22), while other surgical modalities were associated with significantly higher treatment failure (HR 1.68. 95% CI 1.12-2.52). Among men treated from 2011 to 2012, endoscopic enucleations were associated with significantly lower failure than transurethral resection of the prostate (HR: 0.24, 95% CI 0.06-0.97). CONCLUSIONS: Supporting the generalizability of previous randomized trial findings, in real-world practice we found no differences in treatment failure up to 7 years after photoselective vaporization of the prostate or transurethral resection of the prostate. By comparison, endoscopic enucleation, although underused, may be associated with lower rates of treatment failure than transurethral resection of the prostate.
引用
- Frendl DM, Chen YW, Chang DC, et al. A Claims Based Assessment of Reoperation and Acute Urinary Retention after Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia. J Urol. 2020. PMID: 33026901. doi:10.1097/JU.0000000000001390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。